Efficacy, safety and survival with ruxolitinib in patients with smyelofibrosis: Results of a median 2-year follow-up of COMFORT-I

Haematologica

Volumn 98, Issue 12, 2013, Pages 1865-1871

  Verstovsek, Srdan ^a   Mesa, Ruben A ^b   Gotlib, Jason ^c   Levy, Richard S ^d   Gupta, Vikas ^e   Dipersio, John F ^f   Catalano, John V ^g   Deininger, Michael W N ^h   Miller, Carole B ⁱ   Silver, Richard T ^j   Talpaz, Moshe ^k   Winton, Elliott F ^l   Harvey Jr , Jimmie H ^m   Arcasoy, Murat O ⁿ   Hexner, Elizabeth O ^o   Lyons, Roger M ^p   Paquette, Ronald ^q   Raza, Azra ^r   Vaddi, Kris ^d   Erickson Viitanen, Susan ^d   Sun, William ^d   Sandor, Victor ^d   Kantarjian, Hagop M ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

^b MAYO CLINIC   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d Experimental Station   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MONASH UNIVERSITY   (Australia)

^h UNIVERSITY OF UTAH   (United States)

ⁱ St Agnes Cancer Institute   (United States)

^j WEILL CORNELL MEDICAL CENTER   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Birmingham Hematology Oncology   (United States)

ⁿ DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r New York Presbyterian Hospital Columbia University Medical Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RUXOLITINIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; LEG PAIN; MAJOR CLINICAL STUDY; MIDDLE AGED; MORBIDITY; MYELOFIBROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERIPHERAL EDEMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPLEEN FUNCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASES; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PYRAZOLES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84887014885     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.092155     Document Type: Article

References (11)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
2. Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222-30.
3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901.
4. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76.
5. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-91.
6. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127-40.
7. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366 (9):799-807.
8. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-98.
9. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285-92.
10. Cervantes F, Kiladjian JJ, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuitty M, et al. Long-term safety, efficacy, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood. 2012;120. Abstract 801.
11. Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013, 6:81